Safer Warfarin Treatment

N/ASuspendedNCT01042067

Oslo University Hospital200 enrolled

Overview

The study is a national multicenter prospective observational study, including 200 patients. The main purpose of this study is to explore in more detail the influence of genetic variability (CYP enzymes and vitamin K dependent proteins) and dietary vitamin K status on warfarin dosing, clinical effect and adverse events with emphasis on the initial phase of treatment. The hypothesis is that genetic variability concerning CYP enzymes and vitamin K dependent proteins predict dosing and adverse events during warfarin treatment. The main aim is to individualize warfarin therapy and establish a treatment algorithm based on genotype and dietary vitamin K status to make the anticoagulation therapy with warfarin more secure.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Atrial Fibrillation Venous Thrombosis Pulmonary Embolism Heart Valve Prosthesis

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasian * \>18 years of age * included in the study at the onset of warfarin treatment * target INR (2-3 for atrial fibrillation, vein thrombosis, pulmonary embolism and 2.5-3.5 for prosthetic heart valves) * standard indications for warfarin treatment Exclusion Criteria: * Non-caucasian * Clinical significant liver affection * Heart failure, NYHA class III-IV * Non-compliant - not able to accomplish protocol demands * Not able to give informed consent * Long-term antibiotic therapy * Malabsorption conditions and inflammatory bowel disease

Safer Warfarin Treatment

Overview

Conditions

Interventions

Eligibility

Locations (1)